Novo Nordisk and Chip Ganassi Racing Announce Multi-Year Sponsorship AgreementNovo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series.

Kimball, 26, from Camarillo, Calif., is the first licensed driver with type 1 diabetes in the history of INDYCAR to race at the highest level of the series. Diagnosed in 2007, he monitors his blood sugar before, during and after each race. Charlie also uses the Novo Nordisk insulin Levemir® (insulin detemir [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) to help manage his diabetes, administering it with a pre-filled insulin pen device called FlexPen.

“After an exciting first year, we are extremely proud to continue our partnership with Charlie Kimball and Novo Nordisk Chip Ganassi Racing,” said Camille Lee, Corporate Vice President, Diabetes Marketing at Novo Nordisk. “This team represents a unique opportunity for us, as a pharmaceutical company, to raise disease awareness on a broader scale and show everyone that diabetes doesn’t need to slow you down.”

The new agreement begins with the 2012 IZOD IndyCar season and the launch of a new IZOD IndyCar Series car that replaces the race car introduced in 2003. Next year also marks the fourth consecutive year of partnership between Novo Nordisk and Kimball. Following two years of sponsorship of Kimball in the Firestone Indy Lights Series, Novo Nordisk partnered with Chip Ganassi Racing to form Novo Nordisk Chip Ganassi Racing and in December 2010, became the title sponsor of Charlie in his IndyCar rookie season.

“It speaks volumes that a company like Novo Nordisk is making this type of long-term commitment to our team, to Charlie, and the IndyCar Series,” said Chip Ganassi, Owner, Chip Ganassi Racing Teams. “Charlie has done everything that we have asked of him on the track and we certainly feel his future is bright. As for Novo, they have been a tremendous partner both on- and off- the track. The IndyCar Series could use more partners like them.”

Novo Nordisk has also been actively involved in providing information about diabetes awareness at INDYCAR events through the Drive the Switch device awareness program and the award-winning Race with Insulin™ campaign. The team extension also retains the company’s primary sponsorship of Kimball’s race car, race suit and other branding opportunities. Kimball will continue to make appearances on behalf of Novo Nordisk throughout the term of the agreement.

Kimball has posted two top-10 finishes in 2011 at Birmingham and New Hampshire and finished 13th in his debut at the Indianapolis 500. He launched his single-seater racing career in 2002 and has raced in several international series since then, highlighted by a five-win effort in the 2005 British Formula 3 Championship. At that time, Kimball established himself as the first American to win a British Formula 3 race in 11 years.

“My partnership with Novo Nordisk is very unique because they make the insulins I take every day and they produce the delivery device I use to manage my diabetes,” Kimball said. “I am fortunate to have Novo Nordisk and Chip Ganassi Racing support me in my career and I am proud and honored to be associated with these two outstanding organizations.”

Copyright 1999-2014 | AutoRacing1 is an
independent internet online publication and is not affiliated with, sponsored by, or endorsed
by IndyCar, NASCAR, FIA, Sprint, or any other series sponsor.
This material may not be published, broadcast, or redistributed without
permission.